Skip to main content

Table 2 Procedural details of ABSORB II trial

From: Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention

  Bioresorbable scaffold group (n = 335) Metallic stent group (n = 166) Difference (95 % CI) p
Number of lesions 364 182   
Balloon dilatation prior to device implantation 364 (100 %) 180 (99 %) 1.10 % (−0.21, 3.92) 0.11
Planned overlap with the same type of device 56 (15 %) 20 (11 %) 4.40 % (−1.93, 9.94) 0.16
Additional implantation with the same device 14 (4 %) 11 (6.0) −2.20 % (−6.91, 1.44) 0.25
More than one study device implanted 70 (19 %) 27 (15 %) 4.40 % (−2.57, 10.62) 0.21
Nominal size of study device (mm) 3.01 (0.31) 3.05 (0.28) −0.04 (−0.10, 0.01) 0.10
Balloon dilatation after device implantation 221 (61 %) 107 (59 %) 1.92 % (−6.66, 10.67) 0.67
Nominal diameter of balloon used (mm) 3.08 (0.34) 3.16 (0.36) −0.08 (−0.14, 0.01) 0.02
Maximum balloon pressure used (atm) 14.23 (3.43) 15.03 (3.33) −0.80 (−1.4, −0.2) 0.01
Diameter of balloon used (mm) 3.29 (0.35) 3.35 (0.37) −0.06 (−0.14, 0.02 ) 0.15
Angiographic acute recoil of device following implantation per device (mm) 0.19 (0.19) 0.19 (0.18) −0.00 (−0.04, 0.03) 0.85
Device success     
 Clinical device success 361 (99 %) 182 (100 %) −0.82 % (−2.39, 1.31) 0.55
 Clinical procedural success 322 (96 %) 164 (99 %) −2.68 % (−5.46, 0.80) 0.16